Valeant CEO to tell U.S. Senate he regrets raising heart drug prices

WASHINGTON, April 27 (Reuters) - Outgoing Valeant

Pharmaceuticals Chief Executive Michael Pearson plans

to tell a U.S. Senate panel on Wednesday that he regrets his

decision to acquire and jack up...

Read more